Tandem Diabetes (TNDM) Misses Q2 EPS by 82c, Revenues Beat; Offers FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Tandem Diabetes Care Reports Second Quarter 2018 Financial Results
July 30, 2018 4:05 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pump available in the United States, today reported its financial results for the quarter ended June 30, 2018.
Second Quarter 2018 Results
In comparing the second quarter of 2018 to the same period of 2017:
Pump shipments increased 59 percent to 5,447 pumps from 3,427 pumps Sales increased 60 percent to $34.1 million from $21.3 million Operating margin improved to negative 41 percent from negative 89 percent... More
